Pharvaris N.V. (PHVS) News
NASDAQ: PHVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.10-0.02 (-0.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PHVS news summary
We found 2 recent headlines mentioning Pharvaris N.V. (PHVS): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, PHVS is down 0.06% at $31.10. The most recent story, "Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pharvaris N.V. headlines
- Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027(RTTNews) - Pharvaris (PHVS), a late-stage biopharmaceutical company, announced that the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablets to prevent hereditary…NasdaqPHVS, ET
- Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of…GlobeNewswire